ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1581

Impact of Diabetes on Risk of End Stage Renal Disease in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus

Renata Hansen1, Julia Simard 2, Mikkel Faurschou 3, Søren Jacobsen 4 and Titilola Falasinnu 5, 1Copenhagen Lupus and Vasculitis Clinic, Denmark, Stanford, CA, 2Stanford University School of Medicine, Palo Alto, CA, 3Copenhagen Lupus and Vasculitis Clinic, Denmark, Copenhagen, Hovedstaden, Denmark, 4Copenhagen Lupus and Vasculitis Clinic, Denmark, Copenhagen, Denmark, 5Department of Health Research and Policy, Stanford School of Medicine, Palo Alto, CA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: diabetes and end stage kidney disease, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: SLE – Clinical Poster II: Comorbidities

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Risk of end stage renal disease (ESRD) is increased in patients with systemic lupus erythematosus (SLE). Due to lifestyle –related risk factors, inflammation, and medications such as steroids, SLE patients are also more likely to have diabetes mellitus (DM), the leading cause of ESRD in the world. We estimated the impact of DM on ESRD incidence in a large inception cohort of patients with SLE.

Methods: All adult patients registered with SLE International Classification of Diseases (ICD) codes in the Danish National Patient Register (DNPR) from January 1, 1996 to July 31, 2018 were identified. Individuals had no SLE ICD codes prior to 1996 (incident cases, n=3178). The date of this first SLE registration was set as SLE diagnosis date (baseline). DM was defined as the date of first DM ICD code or the date of first filled DM prescription (National Register of Medicinal Product Statistics). ESRD was defined as first registration of dialysis, renal transplant or terminal (stage 5) kidney insufficiency using ICD codes. Patients with prevalent ESRD at baseline were excluded from the analyses (n=29). ESRD incidence was compared in those with DM vs those without DM (non-DM). Incidence rates per 1000 person years (IRs) and incidence rate ratios (IRRs) with corresponding 95% confidence intervals (95% CI) were estimated, stratified by gender, age at baseline (< 50 years vs >= 50 years) and educational level at baseline. Poisson regression estimated IRR.

Results: The DM group included 290 patients of whom 77% were female compared to 85% of the 2859 in the non-DM group. Those with DM were older at baseline (53 vs 46 years) (Table 1). Of those with DM at any time, DM was prevalent at baseline in 119 (41%) and incident in 171 (59%) of the patients. Mean duration from SLE to DM date for patients with incident DM was 6.4 years. Hypertension was more prevalent at baseline in those with DM compared with the non-DM group (35 % vs 20 %). Patients with DM had nearly 3 times higher incidence rate of ESRD compared with non-DM patients, adjusted for gender, age, and educational level (2.6 (1.4-4.9)). The rates were higher in females, patients aged ≥50 years, and those with lower educational level (Figure1). However, due to overlapping CIs these differences might not be significantly different from one another.

Conclusion: We found that DM greatly increased the risk of ESRD in SLE patients. Timely diagnosis and treatment of comorbidities like DM are essential to prevent long term complications and damage accrual in SLE patients.


ESRD_ACR_table_1


ESRD_ACR2_figure1


Disclosure: R. Hansen, None; J. Simard, None; M. Faurschou, None; S. Jacobsen, Bristol-Myers Squibb, 2; T. Falasinnu, None.

To cite this abstract in AMA style:

Hansen R, Simard J, Faurschou M, Jacobsen S, Falasinnu T. Impact of Diabetes on Risk of End Stage Renal Disease in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/impact-of-diabetes-on-risk-of-end-stage-renal-disease-in-danish-nationwide-cohort-of-newly-diagnosed-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-diabetes-on-risk-of-end-stage-renal-disease-in-danish-nationwide-cohort-of-newly-diagnosed-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology